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Lu and colleagues report the structures of b-amyloid fibrils seeded from the brain extracts of two Alzheimer’s
disease patients, a game-changing study that could open new avenues for a structure-based design of
diagnostic imaging agents and aggregation inhibiting drugs.Figure 1. High-Resolution Structure of Ab40
Fibrils Seeded from Alzheimer’s Patient
Tissue
(A) Three-fold symmetry repeat unit illustrating
backbone (gray) and side chain (green) atoms.
(B) View of the idealized structure along the
fibril axis. Adapted from Figure 5 of Lu et al.
(2013) Cell 154, 1257–1268, with permission from
Elsevier.In the September 12 issue ofCell (Lu et al.,
2013), a research team led by Robert
Tycko at the National Institutes of Health
in collaboration with Stephen C. Meredith
at the University of Chicago reported
a landmark study of b-amyloid(1–40)
(Ab40) fibril structures derived from post-
mortem human brain tissue. This work
is a major breakthrough for Alzheimer’s
disease (AD) research and culminates a
decades-long effort to develop technolo-
gies to address this previously intractable
structural problem.
The only established method for solv-
ing atomic-resolution structures of non-
crystalline peptide or protein fibrils is
solid-state nuclear magnetic resonance
(SSNMR) spectroscopy. However, per-
forming SSNMR on specimens extracted
directly from brain tissue was not pre-
viously possible, because such fibrils
were neither isotopically labeled nor in
sufficient quantity to conduct a full
structural study. The investigators solved
this technical problem by (1) extracting
microgram quantities of amyloid plaques
from 1 g of tissue from each patient,
(2) characterizing the fibril fragments
by transmission electron microscopy
(TEM), and then (3) seeding the growth
of synthetic 13C,15N-labeled Ab40.
Although fibrils of such peptides pre-
pared in vitro can have variations in
morphology (Paravastu et al., 2009), the
Lu et al. (2013) study shows that in vivo
morphologies can be faithfully repro-
duced by the seeding protocol in suffi-
cient quantity to carry out SSNMR
measurements, as previously demon-
strated for in vitro samples (Petkova
et al., 2005). This approach enables
structural measurements with an un-1722 Structure 21, October 8, 2013 ª2013 Elprecedented level of detail for the fibrils
underlying AD.
On a technical level, the outcome
is breathtaking, and the publication is
beautifully illustrated with light micro-
scope and TEM images and correspond-
ing two-dimensional and three-dimen-sevier Ltd All rights reservedsional SSNMR data sets and structures.
The authors use the full armament of
spectroscopic tools to perform unambig-
uous backbone assignments, determine
backbone dihedral angles, measure
internuclear distances, and determine
relative orientations of molecular seg-
ments. The data sets give full sequence
coverage and, when combined with
symmetry restraints from dark-field
TEM, simulated annealing calculations
converge to unique structures. In the
past, obtaining such results would have
required years of spectrometer measure-
ment time and dozens of samples with
site-specific isotopic labels, but major
progress in the data collection and inter-
pretation from the SSNMR community
has alleviated this bottleneck. In addition
to studies from the Tycko group, other
research teams have solved structures
of alternative polymorphs (Bertini et al.,
2011) and examined small molecule in-
teractions with Ab40 (Lopez del Amo
et al., 2012), and SSNMR technologies
have been utilized to solve high-resolu-
tion structures of the HET-s(218–289)
prion (Wasmer et al., 2008) among others
(reviewed in Comellas and Rienstra,
2013). Collectively, a powerful set of
SSNMR and TEM methods has emerged
and gives high confidence in the new
structures.
The patient I form yields a 3-fold
symmetric structure (Figure 1) with a
number of significant implications. First,
the authors note that, due to the burial of
C-terminal residues in the fibril core,
quantitation using monoclonal antibodies
specific to C-terminal epitopes may
be unreliable. Conversely, production
of antibodies with complementary
Structure
Previewsspecificities may enable more accurate
assays of pathogenic and non-patho-
genic forms of Ab40 in vivo.
Second, the distinctive conformational
features of brain-derived fibril structures
may provide a basis for the rational design
of small molecule inhibitors or imaging
agents. For example, thioflavin T analogs
such as Pittsburgh compound B have
proved clinically useful as positron emis-
sion tomography imaging agents. The
diagnostic specificity of such compounds
may be enhanced by targeting differences
in conformation between in vivo and
in vitro forms of the fibrils. Such strategies
could have broad implications also for
differential diagnosis of Alzheimer’s, Par-
kinson’s, and other neurodegenerative
disorders (Bagchi et al., 2013).
Finally, the structural results con-
tribute profoundly to the longstanding
debate regarding the etiology and pro-
gression of AD. The results arguestrongly in favor of Ab fibrils as a causa-
tive or at least contributing agent in
AD, yet they also raise a number of sig-
nificant questions. Given the inherent
polymorphism of such small peptides,
why are the fibrils from individual pa-
tients not polymorphic? Is the initial
fibril formation stochastic, and then the
same form predominantly replicated
and transported throughout the brain?
Or are several fibril forms nucleated in
the brain, but some clearance mecha-
nisms are defective, selecting for a
population of one form? Do patients
with common clinical histories have the
same fibril form? If so, can AD diagnosis
and treatment be personalized at the
molecular level?
Answers to these questions are likely
only to be clarified by further studies of
larger patient populations using the fabu-
lous SSNMR technologies now available
and applied in this pioneering study.Structure 21, October 8, 2013REFERENCES
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